FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology. Invention provides a method of treating or preventing heart failure in a mammal, comprising: producing a glial growth factor 2 (GGF2) peptide, having a epidermal growth factor (EGF-like) domain; administering a therapeutically effective amount of said peptide to a mammal at least 96 hours apart, wherein said therapeutically effective amount is effective for treating or preventing cardiac failure in said mammal.
EFFECT: invention enables to preserve and/or improve the therapeutic effect of administering neuregulin, such as glia growth factor 2 (GGF2) or its fragment, with minimizing any potential side effects.
7 cl, 15 dwg, 11 tbl, 1 ex
